WASHINGTON — Even before it was announced, drug makers threatened to sue the Trump administration over a new policy that would require them to include prices in their TV ads.

Now that the proposal is official, the better question about a lawsuit may be “When?” Already on Monday, drug makers doubled down on their argument that the government is violating their First Amendment rights by compelling them to disclosure their prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • No violations of first amendment rights in the required posting of prices. The goal is “public right to know “. Everything for sale is promoted with a price and price competition is routine business.

  • A few weeks ago, our predatory Pharma Industry and their sycophant Azar, were complaining about listing the Side Effects on their products. This deceptive advertising used to be Illegal in the US food for good reason. Drug prices are still rising exponentially and price gouging, is now a perfectly acceptable business practice. Our media normalized all of this and continues to misinform the public.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy